MBL producers rose from 20.4% to 48.6% of US carbapenem-resistant Enterobacterales from 2021 to 2025, while aztreonam-avibactam stayed active against 97.7% of them.
|Videos|December 2, 2016
Reinvigorating the Antibiotic Pipeline
Author(s)Contagion Editorial Staff
John Mohr, PharmD, president and founder of Medical Affairs Strategic Solutions, LLC, discusses global and national initiatives for the development of new antibiotics.
Advertisement
John Mohr, PharmD, president and founder of Medical Affairs Strategic Solutions, LLC, discusses global and national initiatives for the development of new antibiotics.
Interview Transcript (slightly modified for readability)
“There’s a lot of movement at the global level for the development of new antibiotics, from the World Health Organization, to the Centers for Disease Control and Prevention, and recognition that we certainly have a problem that needs to be fixed. It truly is a market failure for why these new, life-saving drugs aren’t being developed. There are incentives that are being proposed in order to attempt to try to reinvigorate the antibiotic pipeline.
There are in general two categories, either a push incentive, to provide reasons for companies to get back in the space, or pull incentives in order to pull the drug through and establish a market for those therapies. A recent report came out from Jim O’Neill, [which] outlined additional steps in order to improve the antibiotic pipeline. Additionally, there’s legislation that’s being passed in the United States, the GAIN Act, as well as other pending legislation, such as the
A lot of work is being done at the global level, and more needs to be done in order to ensure that we have access to these life-saving drugs.”
Advertisement
Related to this article
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Investigational cefiderocol-xeruborbactam inhibited 98.5% of carbapenem-nonsusceptible Acinetobacter and nearly all Enterobacterales in global surveillance data.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.
Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.
Advertisement
Advertisement
Trending on Contagion Live
1
Cefiderocol-Xeruborbactam Active Against Carbapenem-Resistant Bacteria
2
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1
3
Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record
4
Zelicapavir Shortens RSV Symptoms Despite Missing Primary End Point
5